

WORLDWIDE REGISTRATION

dolutegravir/abacavir/lamivudine 5 mg/60 mg/ 30mg
Dispersible Tablet

APPROVAL

US

EU

Switzerland

SUBMISSION

Chile

UK

- ✓ "Approval" means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.
- ✓ Granted Marketing Authorisations may include limitations on the use of the product.

This document was prepared on 07 September 2023 and will be updated on a quarterly basis by ViiV Healthcare. It is made available for information purposes only and ViiV Healthcare accepts no liability arising from the reliance by third parties, on the information provided.